BACKGROUND AND OBJECTIVES: The optimal treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized, blinded, 3-month trial in vitamin D-deficient CKD stage 3 and 4 patients with parathyroid hormone (PTH) values above the Kidney Disease Outcomes Quality Initiative target, comparing cholecalciferol (4000 IU/d x 1 month, then 2000 IU/d; n = 22) to doxercalciferol (1 microg/d; n = 25). RESULTS: There was no difference in baseline demographics or lab tests, except a slightly higher estimated GFR (eGFR) in the doxercalciferol group. There was a significant increase in vitamin D level in the cholecalciferol group (14 +/- 6 to 37 +/- 10 ng/ml; P < 0.001) but no change in the doxercalciferol group. The PTH decreased by 27% +/- 34% in the doxercalciferol group (P = 0.002) and decreased by 10% +/- 31% in the cholecalciferol group (P = 0.16), but the difference between treatments was NS (P = 0.11). Similar results were found when absolute PTH change from baseline to end point was analyzed in a repeated-measures ANOVA model. The serum calcium and urine calcium excretions were not different. Additional non-mineral-related end points, albuminuria, and BP were evaluated, and although trends were present, this did not reach significance. CONCLUSIONS: This prospective, randomized trial demonstrated a within-group reduction in PTH in the doxercalciferol-treated patients but no significant difference between the doxercalciferol and cholecalciferol patients. Larger, long-term studies are needed to demonstrate efficacy of mineral-related and non-mineral-related end points and safety.
RCT Entities:
BACKGROUND AND OBJECTIVES: The optimal treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized, blinded, 3-month trial in vitamin D-deficient CKD stage 3 and 4 patients with parathyroid hormone (PTH) values above the Kidney Disease Outcomes Quality Initiative target, comparing cholecalciferol (4000 IU/d x 1 month, then 2000 IU/d; n = 22) to doxercalciferol (1 microg/d; n = 25). RESULTS: There was no difference in baseline demographics or lab tests, except a slightly higher estimated GFR (eGFR) in the doxercalciferol group. There was a significant increase in vitamin D level in the cholecalciferol group (14 +/- 6 to 37 +/- 10 ng/ml; P < 0.001) but no change in the doxercalciferol group. The PTH decreased by 27% +/- 34% in the doxercalciferol group (P = 0.002) and decreased by 10% +/- 31% in the cholecalciferol group (P = 0.16), but the difference between treatments was NS (P = 0.11). Similar results were found when absolute PTH change from baseline to end point was analyzed in a repeated-measures ANOVA model. The serum calcium and urine calcium excretions were not different. Additional non-mineral-related end points, albuminuria, and BP were evaluated, and although trends were present, this did not reach significance. CONCLUSIONS: This prospective, randomized trial demonstrated a within-group reduction in PTH in the doxercalciferol-treated patients but no significant difference between the doxercalciferol and cholecalciferolpatients. Larger, long-term studies are needed to demonstrate efficacy of mineral-related and non-mineral-related end points and safety.
Authors: Robert E LaClair; Richard N Hellman; Sharon L Karp; Michael Kraus; Susan Ofner; Qian Li; Karen L Graves; Sharon M Moe Journal: Am J Kidney Dis Date: 2005-06 Impact factor: 8.860
Authors: Rachel L Perlman; Fredric O Finkelstein; Lei Liu; Erik Roys; Margaret Kiser; George Eisele; Sally Burrows-Hudson; Joseph M Messana; Nathan Levin; Sanjay Rajagopalan; Friedrich K Port; Robert A Wolfe; Rajiv Saran Journal: Am J Kidney Dis Date: 2005-04 Impact factor: 8.860
Authors: Rajiv Agarwal; Muralidhar Acharya; Jin Tian; Richard L Hippensteel; Joel Z Melnick; Ping Qiu; Laura Williams; Daniel Batlle Journal: Kidney Int Date: 2005-12 Impact factor: 10.612
Authors: Aristeidis Stavroulopoulos; Christine J Porter; Simon D Roe; David J Hosking; Michael J D Cassidy Journal: Nephrology (Carlton) Date: 2008-02 Impact factor: 2.506
Authors: Jessica Kendrick; Emily Andrews; Zhiying You; Kerrie Moreau; Kristen L Nowak; Heather Farmer-Bailey; Douglas R Seals; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2017-08-07 Impact factor: 8.237
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902
Authors: Lindsay M Griffin; Michelle R Denburg; Justine Shults; Susan L Furth; Isidro B Salusky; Wenke Hwang; Mary B Leonard Journal: Pediatr Nephrol Date: 2012-10-20 Impact factor: 3.714